Alexander Edward Perl, MD, MS
Associate Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania
Department: Medicine
Contact information
Perelman Center for Advanced Medicine
Division of Hematology-Oncology
University or Pennsylvania
3400 Civic Center Blvd
12th Floor, South Pavilion
Office #12-154
Philadelphia, PA 19104
Division of Hematology-Oncology
University or Pennsylvania
3400 Civic Center Blvd
12th Floor, South Pavilion
Office #12-154
Philadelphia, PA 19104
Office: 215-662-4794
Fax: 215-615-5887
Fax: 215-615-5887
Education:
BA (Psychology)
University of Rochester, 1993.
MD (Internal Medicine)
Mount Sinai School of Medicine, 1997.
MS (Translational Research)
University of Pennsylvania, 2011.
Permanent linkBA (Psychology)
University of Rochester, 1993.
MD (Internal Medicine)
Mount Sinai School of Medicine, 1997.
MS (Translational Research)
University of Pennsylvania, 2011.
Description of Research Expertise
Dr. Alexander Perl is a member of the leukemia program in the Abramson Cancer Center and an Associate Professor in the Division of Hematology/Oncology at the Perelman School of Medicine at the University of Pennsylvania. His research focuses on molecularly-targeted therapeutics for acute leukemia. His principal expertise is in FLT3 inhibitors for AML and he has played a leading role in clinical trails of these agents. He also studies other agents targeting signal transduction, such as tyrosine kinase inhibitors for Ph-like ALL and inhibitors of oncogenic PI3K/AKT/mTOR signaling. His laboratory studies focus on phospho-specific flow cytometry of fixed, unfractionated blood and marrow as a method to quantify pharmacodynamic response to signal transduction inhibitors. He is additionally interested in preclinical drug screening in cellular and murine xenotransplantation models of acute leukemia.Description of Clinical Expertise
Dr. Perl specializes in the care of patients with acute leukemia (AML and ALL), myelodysplastic syndromes (MDS), and CML.Selected Publications
Perl Alexander E, Martinelli Giovanni, Cortes Jorge E, Neubauer Andreas, Berman Ellin, Paolini Stefania, Montesinos Pau, Baer Maria R, Larson Richard A, Ustun Celalettin, Fabbiano Francesco, Erba Harry P, Di Stasi Antonio, Stuart Robert, Olin Rebecca, Kasner Margaret, Ciceri Fabio, Chou Wen-Chien, Podoltsev Nikolai, Recher Christian, Yokoyama Hisayuki, Hosono Naoko, Yoon Sung-Soo, Lee Je-Hwan, Pardee Timothy, Fathi Amir T, Liu Chaofeng, Hasabou Nahla, Liu Xuan, Bahceci Erkut, Levis Mark J: Gilteritinib or Chemotherapy for Relapsed or Refractory -Mutated AML. The New England journal of medicine 381(18): 1728-1740, 10 2019.McMahon Christine M, Ferng Timothy, Canaani Jonathan, Wang Eunice S, Morrissette Jennifer J D, Eastburn Dennis J, Pellegrino Maurizio, Durruthy-Durruthy Robert, Watt Christopher D, Asthana Saurabh, Lasater Elisabeth A, DeFilippis RosaAnna, Peretz Cheryl A C, McGary Lisa H F, Deihimi Safoora, Logan Aaron C, Luger Selina M, Shah Neil P, Carroll Martin, Smith Catherine C, Perl Alexander E: Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia. Cancer discovery 9(8): 1050-1063, Aug 2019.
Brown FC, Wang X, Birkinshaw RW, Chua CC, Morley TD, Kasapgil S, Pomilio G, Blombery P, Huang DCS Professor, Czabotar PE, Priore SF, Yang G, Carroll MP, Wei AH, Perl AE. : Acquired BCL2 variants associated with venetoclax resistance in acute myeloid leukemia. Blood Adv. 9: 127-131, Oct 2024 Notes: in press, epub online.
Levis MJ, Hamadani M, Logan B, Jones RJ, Singh AK, Litzow M, Wingard JR, Papadopoulos EB, Perl AE, Soiffer RJ, Ustun C, Ueda Oshima M, Uy GL, Waller EK, Vasu S, Solh M, Mishra A, Muffly L, Kim HJ, Mikesch JH, Najima Y, Onozawa M, Thomson K, Nagler A, Wei AH, Marcucci G, Geller NL, Hasabou N, Delgado D, Rosales M, Hill J, Gill SC, Nuthethi R, King D, Wittsack H, Mendizabal A, Devine SM, Horowitz MM, Chen YB; BMT-CTN 1506/MORPHO Study Investigators.: Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of FLT3. J Clin Oncol 42: 1766-1775, May 2024.
Smith Catherine C, Zhang Chao, Lin Kimberly C, Lasater Elisabeth A, Zhang Ying, Massi Evan, Damon Lauren E, Pendleton Matthew, Bashir Ali, Sebra Robert, Perl Alexander, Kasarskis Andrew, Shellooe Rafe, Tsang Garson, Carias Heidi, Powell Ben, Burton Elizabeth A, Matusow Bernice, Zhang Jiazhong, Spevak Wayne, Ibrahim Prabha N, Le Mai H, Hsu Henry H, Habets Gaston, West Brian L, Bollag Gideon, Shah Neil P: Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 "Gatekeeper" F691L Mutation with PLX3397. Cancer Discovery 5(6): 668-79, Jun 2015.
Erba HP, Montesinos P, Kim HJ, Patkowska E, Vrhovac R, Žák P, Wang PN, Mitov T, Hanyok J, Kamel YM, Rohrbach JEC, Liu L, Benzohra A, Lesegretain A, Cortes J, Perl AE, Sekeres MA, Dombret H, Amadori S, Wang J, Levis MJ, Schlenk RF; QuANTUM-First Study Group.: Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 401: 1571-1583, May 2023.
Li Sheng, Garrett-Bakelman Francine, Perl Alexander E, Luger Selina M, Zhang Chao, To Bik L, Lewis Ian D, Brown Anna L, D Andrea Richard J, Ross M, Levine Ross, Carroll Martin, Melnick Ari, Mason Christopher E: Dynamic evolution of clonal epialleles revealed by methclone. Genome Biology 15(9): 472, Sep 2014.
Perl AE*, Altman JK*, Cortes JE, Smith CC, Litzow M, Baer MR, Claxton D. Erba H, Gill S, Goldberg S, Jurcic JA, Larson RA, Liu C, Ritchie EK, Sargent B, Schiller G, Spira AI, Strickland SA, Tibes R, Ustun C, Wang ES, Stuart RK, Röllig C, Neubauer A, Martinelli G, Bahceci E, Levis MJ (*equal contribution) : Selective Inhibition of FLT3 by Gilteritinib in Relapsed/Refractory Acute Myeloid Leukaemia: a Multicentre, First-in-human, Open-label, Phase 1/2 Study. Lancet Oncology August 2017.
Nybakken G E, Canaani J, Roy D, Morrissette J D, Watt C D, Shah N P, Smith C C, Bagg A, Carroll M, Perl A E: Quizartinib elicits differential responses that correlate with karyotype and genotype of the leukemic clone. Leukemia 30(6): 1422-5, Jun 2015 Notes: Epub ahead of print.
Smith Catherine Choy, Lasater Elisabeth A, Lin Kimberly C, Wang Qi, McCreery Melissa Quino, Stewart Whitney K, Damon Lauren E, Perl Alexander E, Jeschke Grace R, Sugita Mayumi, Carroll Martin, Kogan Scott C, Kuriyan John, Shah Neil P: Crenolanib is a selective type I pan-FLT3 inhibitor. Proceedings of the National Academy of Sciences of the United States of America 111(14): 5319-24, Apr 2014.
Schaab C, Oppermann F S, Klammer M, Pfeifer H, Tebbe A, Oellerich T, Krauter J, Levis M, Perl A E, Daub H, Steffen B, Godl K, Serve H: Global phosphoproteome analysis of human bone marrow reveals predictive phosphorylation markers for the treatment of acute myeloid leukemia with quizartinib. Leukemia 28(3): 716-9, Mar 2014.
Perl Alexander E, Kasner Margaret T, Shank Doris, Luger Selina M, Carroll Martin: Single-cell pharmacodynamic monitoring of S6 ribosomal protein phosphorylation in AML blasts during a clinical trial combining the mTOR inhibitor sirolimus and intensive chemotherapy. Clinical Cancer Research : an official journal of the American Association for Cancer Research 18(6): 1716-25, Mar 2012.
Luskin Marlise R, Huen Auris O, Brooks Sarah A, Stewart Campbell, Watt Christopher D, Morrissette Jennifer J D, Lieberman David B, Bagg Adam, Rosenbach Misha, Perl Alexander E: NPM1 Mutation is Associated with Leukemia Cutis in Acute Myeloid Leukemia with Monocytic Features. Haematologica 100(10): 412-4, Oct 2015.
Sanchez PV, Perry RL, Sarry JE, Perl AE, Murphy K, Swider CR, Bagg A, Choi JK, Biegel JA, Danet-Desnoyers G, Carroll M: A robust xenotransplantation model for acute myeloid leukemia. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 23(11): 2109-2117, Nov 2009.
Perl AE, Kasner MT, Tsai DE, Vogl DT, Loren AW, Schuster SJ, Porter DL, Stadtmauer EA, Goldstein SC, Frey NV, Nasta SD, Hexner EO, Swider C, Bagg A, Gewirtz AM, Carroll M, Luger SM: A Phase I Study of the mTOR Inhibitor Sirolimus and MEC Chemotherapy in Relapsed and Refractory Acute Myeloid Leukemia. Clinical Cancer Research 15(21): 6732-9, November 2009.
Ward Patrick S, Patel Jay, Wise David R, Abdel-Wahab Omar, Bennett Bryson D, Coller Hilary A, Cross Justin R, Fantin Valeria R, Hedvat Cyrus V, Perl Alexander E, Rabinowitz Joshua D, Carroll Martin, Su Shinsan M, Sharp Kim A, Levine Ross L, Thompson Craig B: The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 17(3): 225-34, Mar 2010.
Levis Mark, Ravandi Farhad, Wang Eunice S, Baer Maria R, Perl Alexander, Coutre Steven, Erba Harry, Stuart Robert K, Baccarani Michele, Cripe Larry D, Tallman Martin S, Meloni Giovanna, Godley Lucy A, Langston Amelia A, Amadori Sergio, Lewis Ian D, Nagler Arnon, Stone Richard, Yee Karen, Advani Anjali, Douer Dan, Wiktor-Jedrzejczak W, Juliusson Gunnar, Litzow Mark R, Petersdorf Stephen, Sanz Miguel, Kantarjian Hagop M, Sato Takashi, Tremmel Lothar, Bensen-Kennedy Debra M, Small Donald, Smith B Douglas: Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. Blood 117(12): 3294-301, Mar 2011.
Smith Catherine C, Wang Qi, Chin Chen-Shan, Salerno Sara, Damon Lauren E, Levis Mark J, Perl Alexander E, Travers Kevin J, Wang Susana, Hunt Jeremy P, Zarrinkar Patrick P, Schadt Eric E, Kasarskis Andrew, Kuriyan John, Shah Neil P: Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature 485(7397): 260-3, May 2012.
Sexauer Amy, Perl Alexander, Yang Xiaochuan, Borowitz Michael, Gocke Christopher, Rajkhowa Trivikram, Thiede Christian, Frattini Mark, Nybakken Grant E, Pratz Keith, Karp Judith, Smith B Douglas, Levis Mark: Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML. Blood 120(20): 4205-14, Nov 2012.
Gojo I, Perl A, Luger SM, Baer MR, Norsworthy KJ, Bauer KS, Tidwell M, Fleckinger S, Carroll M, and Sausville EA. : Phase 1 Study of UCN-01 in Combination with Perifosine in Patients with Relapsed and Refractory Acute Leukemias and High Risk Myelodysplastic Syndromes (MDS). Invest New Drugs 31(5): 1217-27, October 2013.
Dinardo Courtney D, Propert Kathleen J, Loren Alison W, Paietta Elisabeth, Sun Zhuoxin, Levine Ross L, Straley Kimberly S, Yen Katharine, Patel Jay P, Agresta Samuel, Abdel-Wahab Omar, Perl Alexander E, Litzow Mark R, Rowe Jacob M, Lazarus Hillard M, Fernandez Hugo F, Margolis David J, Tallman Martin S, Luger Selina M, Carroll Martin: Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia. Blood 121(24): 4917-24, Jun 2013 Notes: Epub ahead of print, May 2, 2013.
Landsburg Daniel J, Stadtmauer Edward, Loren Alison, Goldstein Steven, Frey Noelle, Nasta Sunita D, Porter David L, Tsai Donald E, Perl Alexander E, Hexner Elizabeth O, Luger Selina: Receipt of maintenance therapy is most predictive of survival in older acute lymphoblastic leukemia patients treated with intensive induction chemotherapy regimens. American Journal of Hematology 88(8): 657-60, Aug 2013.
Varadarajan N, Boni A, Elder DE, Bagg A, Micheletti R, Perl AE, Rosenbach M: FLT3 inhibitor-associated neutrophilic dermatoses. JAMA Dermatology 152(2): 480-2, April 2016.
Tasian SK, Hurtz C, Wertheim GB, Bailey N, Lim M, Harvey R, Chen I-M, Willman C, Astles R, Reshmi S, Li M, Frey NV, Selina Luger SM, Carroll M, Perl AE: High incidence of Philadelphia chromosome-negative acute lymphoblastic leukemia (Ph-like ALL) among older adults with B-ALL. Leukemia January 2017.
McMahon Christine M, Canaani Jonathan, Rea Bryan, Sargent Rachel L, Qualtieri Julianne N, Watt Christopher D, Morrissette Jennifer J D, Carroll Martin, Perl Alexander E: Gilteritinib induces differentiation in relapsed and refractory -mutated acute myeloid leukemia. Blood advances 3(10): 1581-1585, May 2019.
Hurtz, C., Wertheim, G. B., Loftus, J. P., Blumenthal, D., Lehman, A., Li, Y., Bagashev, A., Manning, B., Cummins, K. D., Burkhardt, J. K., Perl, A. E., Carroll, M., Tasian, S. K.: Oncogene-independent BCR-like signaling adaptation confers drug resistance in Ph-like ALL. J Clin Invest 130(7): 3637-3653, Jul 2020.
Tarver, T. C., Hill, J. E., Rahmat, L., Perl, A. E., Bahceci, E., Mori, K., Smith, C. C.: Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations. Blood Adv 4(3): 514-524, Feb 2020.
Peretz CAC, McGary LHF, Kumar T, Jackson H, Jacob J, Durruthy-Durruthy R, Levis MJ, Perl AE, Huang BJ, Smith CC: Single Cell DNA Sequencing Reveals Complex Mechanisms of Resistance to Quizartinib Blood Adv. 5(5): 1437-1441, Mar 2021.
Daver N, Perl AE, Maly J, Levis M, Ritchie E, Litzow M, McCloskey J, Smith CC, Schiller G, Bradley T, Tiu RV, Naqvi K, Dail M, Brackman D, Siddani S, Wang J, Chyla B, Lee P, Altman JK.: Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia. J Clin Oncol 40: 4048-4059, Jul 2022.
Pratz KW, Cherry M, Altman JK, Cooper BW, Podoltsev NA, Cruz JC, Lin TL, Schiller GJ, Jurcic JG, Asch A, Wu R, Hill JE, Gill SC, James AJ, Rich ES, Hasabou N, Perl AE, Levis MJ: Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AML. J Clin Oncol 41: 4236-4246, Sep 2023.
Perl AE, Larson RA, Podoltsev NA, Strickland S, Wang ES, Atallah E, Schiller GJ, Martinelli G, Neubauer A, Sierra J, Montesinos P, Recher C, Yoon SS, Maeda Y, Hosono N, Onozawa M, Kato T, Kim HJ, Hasabou N, Nuthethi R, Tiu R, Levis MJ: Outcomes in Patients with FLT3-Mutated Relapsed/ Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage Chemotherapy. Transplant Cell Ther Apr 2023.
Issa GC, Aldoss I, Thirman MJ, DiPersio J, Arellano M, Blachly JS, Mannis GN, Perl A, Dickens DS, McMahon CM, Traer E, Zwaan CM, Grove CS, Stone R, Shami PJ, Mantzaris I, Greenwood M, Shukla N, Cuglievan B, Kovacsovics T, Gu Y, Bagley RG, Madigan K, Chudnovsky Y, Nguyen HV, McNeer N, Stein EM.: Menin Inhibition With Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101). J Clin Oncol Aug 2024.
Levis M, Perl A, Schiller G, Fathi AT, Roboz G, Wang ES, Altman J, Rajkhowa T, Ando M, Suzuki T, Subach RA, Maier G, Madden T, Johansen M, Cheung K, Kurman M, Smith C.: A phase 1 study of the irreversible FLT3 inhibitor FF-10101 in relapsed or refractory acute myeloid leukemia. Blood Adv 8: 2527-2535, May 2024.